The European Society for Medical Oncology (ESMO) is delighted to invite you to ESMO Oncology Summit India 2012. For the second year in succession this state of the art education programme available to Indian Oncologists is being conducted in 4 Indian cities, New Delhi, Kolkata, Chennai and Mumbai in association with CME Mediquest. The scientific programme consists of the latest clinical developments and current best practice recommendations for the management of patients presenting with Breast, Colorectal, and Lung Cancer. Presentations will be followed by interactive discussions and Q&A sessions.

 

 

 

Note: The 13th March Session in Mumbai will be webcast. To watch the online webcast please click here

 

 

Scientific Program & Faculty:

 


Dr. Johan Vansteenkiste MD, PhD

Lecture Title:

• How Does Optimal Staging Influences Treatment Choices for
    Stage III NSCLC

 

Professor Johan Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital.

Professor Vansteenkiste studied Medicine at the Catholic University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the Catholic University of Leuven in 1996.

Professor Vansteenkiste is an active member of different national and international societies such as IASLC, ASCO, ESMO,ERS, and others. He is member of the Board of Directors of IASLC in 2009-2013 and since 2009 a member of the ESMO Faculty. He is Secretary of the Thoracic Oncology Assembly of the ERS from 2009-2012, and member of the ERS School Board.

He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor at the Journal of Thoracic Oncology, member of the editorial board of the Journal of Clinical Oncology and several other journals, and author or co-author of more than 180 peer-reviewed papers and book chapters on Respiratory Oncology.

Professor Vansteenkiste is the recipient of several awards, including the 'Eli-Lilly L. Hertel Chair in Respiratory Oncology',the 'Amgen Chair in Supportive Cancer Care', the 'AstraZeneca Chair in Personalized Lung Cancer Treatment', and the 'JF Peterbroeck Chair in Translational Lung Cancer Research'at the Catholic University of Leuven.



Dr. Andrés Cervantes MD, PhD

Lecture Title:

• Selecting Therapy for Advanced Colorectal Cancer Patients

Associate Professor Andrés Cervantes completed his training period in Medical Oncology in 1986. Thereafter, he completed two years as a Research Fellow in the Oncology Lab at the Free University of Amsterdam with Professor HM Pinedo, where he received his PhD, working on the mechanism of resistance to chemotherapy. Since 1988, he has worked in the Haematology and Medical Oncology Department at the University Hospital in Valencia, Spain and is currently Associate Professor of Medicine and Head of Section of the Haematology and Medical Oncology Department.

Associate Professor Cervantes is an active investigator in gastrointestinal and ovarian cancer, as well in new drug development. He has authored more than 120 scientific articles published in peer-reviewed journals and actively gives educational talks on these topics. Since 2006, he has been a member of the Educational Committee of ESMO. He is currently Chair of the ESMO Guidelines Working Group and is a board member of the ESMO Executive Board.



Prof. Dr. med. Bernhard C. Pestalozzi

Lecture Title:

• New Treatment Aspects in The Management of Early / Late-Stage
    Breast Cancer

Professor Bernhard Pestalozzi commenced his medical studies in 1975 at the University of Geneva, Switzerland. He returned in 1981 to Zurich for a postgraduate course in experimental biology and medicine, where he did basic research in immunology and virology for two and a half years in the laboratory of Prof. Rolf Zinkernagel (who in 1992 was awarded the Nobel-prize).

Professor Pestalozzi´s clinical career started in 1984 in internal medicine at the Cantonal Hospital in Schaffhausen, continuing in 1986 at the University Hospital in Zurich where he later specialized in haematology and oncology. In 1991 he became a fellow at the US-American National Cancer Institute in Bethesda, Maryland. In 1993 he returned to Switzerland as an attending physician at the oncology department in Zurich, specializing in breast cancer and became a member of the scientific committee of IBCSG (International Breast Cancer Study Group). In 1998 he was granted “habilitation” by the University of Zurich and in 2008 was promoted to professor by the University of Zurich and received tenure-track status (“Leitender Arzt”) in the University Hospital.

Professor Pestalozzi research is mostly in the field of breast cancer, focusing recently on brain metastases. Clinically, he is much involved with GI-cancer, particularly at the Swiss HPB-center for hepato-pancreatico-biliary diseases. Since 2006 he has been a member of the ESMO Faculty.


 

About European Society for Medical Oncology


The European Society for Medical Oncology (ESMO) is the leading European professional organization, committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.
Since its founding in 1975 as a non-profit organization, ESMO’s mission has been to advance cancer care and cure. We achieve this through fostering and disseminating good science that leads to better medicine and determines best practice. In this way ESMO fulfils its goal to support oncology professionals in providing people with cancer with the most effective treatments available and the high-quality care they deserve.
The myESMO community is a powerful alliance of more than 7,000 committed oncology professionals from over 120 countries. As a trusted organization with 35 years of experience and over 500 expert committee members, ESMO serves its members and the oncology community through:

Excellence in post-graduate oncology education and training
• Leadership in transforming evidence-based research into standards of cancer care in Europe
• Dedicated efforts to foster a more favorable environment for scientific research
• Innovative international platforms to share expertise, best practices and disseminate the most up-to-date scientific research to
  as wide an audience as possible.

ESMO’s scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place for medical oncologists to update their knowledge, network and exchange ideas.
ESMO also unites key oncology stakeholders and forges strategic partnerships to address critical issues related to the profession and practice of medical oncology. Recognized as an authoritative voice in the fight against cancer, ESMO is pleased to offer consultative expertise to oncology organizations and European authorities on important issues related to cancer research, prevention, diagnosis, treatment and care.